CJC-1295 / IpamorelinBlend

CJC-1295 / Ipamorelin is the classic compounded growth-hormone secretagogue blend, pairing a GHRH analog (CJC-1295) with a selective ghrelin-receptor agonist (ipamorelin). The rationale is that the two stimulate growth-hormone release through complementary pathways, which proponents argue produces a larger, more physiologic GH pulse than either alone. It is sold research-use-only, is not an approved drug, and has no clinical trials as a combination.

CJC-1295 acts as a GHRH-receptor agonist on pituitary somatotrophs, while ipamorelin activates the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). Because GHRH and ghrelin pathways act through different receptors and second messengers, co-stimulation is proposed to be additive or synergistic on pulsatile GH release, which raises hepatic IGF-1. This two-pathway rationale is mechanistically reasonable but the specific combination has not been formally characterized in controlled studies.

There are no human trials of the CJC-1295/Ipamorelin blend; evidence comes from each component separately. CJC-1295 has small early-phase human PK/PD studies showing multi-day elevation of GH and IGF-1 in healthy adults; ipamorelin reached a phase 2 trial (for postoperative ileus) that was well tolerated but did not meet its primary endpoint, and its selectivity data are from animals. No controlled human evidence supports the combination for body composition, anti-aging or performance.

The combined-injection safety has not been studied. Both are growth-hormone secretagogues, so the combination can be expected to raise GH/IGF-1 and may affect glucose metabolism and fluid balance; injection-site reactions, flushing and water retention are the most commonly noted component effects. GH-axis stimulants and their analogs are WADA-prohibited (S2), so this blend is banned in sport. Neither component is FDA-approved, and long-term human safety is unestablished. Research-use only; nothing here is therapeutic or dosing guidance.